farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2020.049farmaec-420Research ArticleORIGINAL ARTICLESОРИГИНАЛЬНЫЕ ПУБЛИКАЦИИChemomicrobiomic analysis of glucosamine sulfate, prebiotics and non-steroidal anti-inflammatory drugsХемомикробиомный анализ глюкозамина сульфата, пребиотиков и нестероидных противовоспалительных препаратовhttps://orcid.org/0000-0002-7663-710XГромоваО. А.GromovaO. A.

Громова Ольга Алексеевна – д.м.н., профессор, в.н.с., научный руководитель Института фармакоинформатики; в.н.с., Author ID: 94901, Scopus Author ID: 7003589812, WoS ResearcherID: J-4946-2017, РИНЦ SPIN-код: 6317-9833, ул. Вавилова, д. 44, корп. 2, Москва 119333, Россия; Ленинские горы, д. 1, Москва 119991, Россия

Olga A. Gromova – MD, Dr Sci Med, Professor, Senior Researcher, Scientific Director of the Federal Research Center “Informatics and Management”, Russian Academy of Sciences; Leading Researcher, Center for Big Data Analysis, Author ID: 94901, Scopus Author ID: 7003589812, WoS ResearcherID: J-4946-2017, RSCI SPIN-code: 6317-9833, 34A Kashirskoye Shosse, Moscow 115522, Russia; 1 Leninskie gory, Moscow 119991, Russia

unesco.gromova@gmail.comhttps://orcid.org/0000-0002-2659-7998ТоршинИ. Ю.TorshinI. Yu.

Торшин Иван Юрьевич – к.ф-м.н., к.х.н., с.н.с., Институт фармакоинформатики, Scopus Author ID: 7003300274, Author ID: 54104; WoS ResearcherID: C-7683-2018, РИНЦ SPIN-код: 1375-1114, ул. Вавилова, д. 44, корп. 2, Москва 119333, Россия;  Ленинские горы, д. 1, Москва 119991, Россия

Ivan Yu. Torshin – MD, PhD, Senior Researcher, Federal Research Center “Informatics and Management”, Russian Academy of Sciences; Big Data Storage and Analysis Center, Scopus Author ID: 7003300274, Author ID: 54104, WoS ResearcherID: C-7683-2018, RSCI SPIN-code: 1375-1114, 34A Kashirskoye Shosse, Moscow 115522, Russia; 1 Leninskie gory, Moscow 119991, Russia

https://orcid.org/0000-0002-6253-621XНаумовА. В.NaumovA. V.

Наумов Антон Вячеславович – д.м.н., профессор, зав. лабораторией заболеваний костно-мышечной системы, AuthorID 393279, РИНЦ SPIN-код 4763-9738, ул. Островитянова, д. 1, Москва 117997, Россия

Anton V. Naumov – MD, Dr Sci Med, Professor, head of the laboratory of diseases of the musculoskeletal system of the Russian gerontological scientific clinical center, AuthorID 393279, RSCI SPIN-code: 4763-9738, 1 Ostrovityanova Str., Moscow 117997, Russia

МаксимовВ. А.MaksimovV. A.

Максимов Валерий Алексеевич – д.м.н., профессор, заслуженный деятель науки Российской Федерации, заслуженный врач Российской Федерации, вице-президент научного общества гастроэнтерологов России, профессор кафедры диетологии и нутрициологии, ул. Баррикадная, д. 2, стр. 1, Москва 123995, Россия

Valery A. Maksimov – MD, Dr Sci Med, Professor, Honored Scientist of the Russian Federation, Honored Doctor of the Russian Federation, Vice President of the Scientific Society of Gastroenterologists of Russia, Professor of the Department of Dietetics and Nutrition, 2-1 Barrikadnaya Str., Moscow 123995, Russia

Федеральный исследовательский центр «Информатика и управление» РАН (ФИЦ ИУ РАН); Центр хранения и анализа больших данных, Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В. Ломоносова»РоссияV.A. Nasonov Research Institute of Rheumatology; Moscow State UniversityRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияPirogov Russian National Research Medical UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования»РоссияRussian Medical Academy of Postgraduate EducationRussian Federation202017112020133270282Copyright © Gromova O.A., Torshin I.Y., Naumov A.V., Maksimov V.A., 20202020Громова О.А., Торшин И.Ю., Наумов А.В., Максимов В.А.Gromova O.A., Torshin I.Y., Naumov A.V., Maksimov V.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/420Introduction

Introduction. The pharmaceutical drugs used in the treatment of osteoarthritis (OA) differ not only in the mechanisms of anti-inflammatory action but also in the effects on the human microbiome.

Purpose

Purpose. Evaluation of the influence of some drugs used in the therapy of OA on the human microbiome by the method of chemoinformation analysis.

Materials and methods

Materials and methods. Сomparative chemomicrobiome analysis of glucosamine sulfate (GS), diclofenac, acetylsalicylic acid (ASA), and three prebiotics (lactose, lactulose, fructose) as molecules of comparison. For each substance, estimates of the area under the curve (AUC) were obtained for a representative sampling of human microbiota (38 commensal bacteria). The minimum inhibitory concentrations (MIC) were established for more than 120 pathogenic bacteria.

Results

Results. On average, according to a representative sampling of microbiota, the profile of the action of GS on the microbiome was almost identical to the profile of the action of lactose (AUC=0.23±0.18). The most effective growth of the microbiome was provided by fructose and lactulose (AUC=0.58±0.21). The effects of diclofenac and ASA on the commensals of microbiome were comparable to the effects of GS (AUC=0.27±0.22). However, the analysis of the obtained MIC values for pathogenic bacteria showed that diclofenac supported the growth of the pathogenic flora (MIC=35±1.4 μg/ml) to a greater extent than GS (MIC=16±1.5 μg/ml) and ASA (MIC=23±2.2 μg/ml).

Conclusion

Conclusion. The effects of GS on the microbiome are comparable to the effects of the prebiotic lactose whereas the inhibitory effect of GS and ASA on pathogenic bacteria is more pronounced than that of diclofenac. The inhibition of pathogenic bacteria by the GS helps to reduce inflammation.

Введение

Введение. Фармацевтические препараты, используемые в терапии остеоартрита (ОА), отличаются не только по механизмам противовоспалительного действия, но и различным воздействием на микробиом человека.

Цель

Цель. Оценка воздействия на микробиом ряда препаратов, используемых в терапии ОА методом хемоинформационного анализа.

Материалы и методы

Материалы и методы. Сравнительный хемомикробиомный анализ глюкозамина сульфата (ГС), диклофенака, ацетилсалициловой кислоты (АСК) и трех пребиотиков как молекул сравнения (лактозы, лактулозы, фруктозы). Для каждого из веществ получены оценки значений площади под кривой роста (AUC) для репрезентативной выборки микробиоты человека (38 бактерий-комменсалов). Также выполнено определение их минимальных ингибирующих концентраций (MIC) для более чем 120 болезнетворных бактерий.

Результаты

Результаты. В среднем по репрезентативной выборке микробиоты профиль действия ГС на микробиом был практически идентичен профилю действия лактозы (AUC=0,23±0,18). Наиболее эффективно рост микробиома поддерживался фруктозой и лактулозой (AUC=0,58±0,21). Эффекты диклофенака и АСК на микробиом были сопоставимы с эффектами ГС (AUC=0,27±0,22). Однако анализ полученных значений MIC для болезнетворных микроорганизмов показал, что диклофенак в большей степени поддерживал рост патогенной флоры (MIC=35±1,4 мкг/мл), чем ГС (MIC=16±1,5 мкг/мл) и АСК (MIC=23±2,2 мкг/мл).

Заключение

Заключение. Эффекты ГС на микробиом сравнимы с эффектами пребиотика лактозы, а ингибирующее воздействие ГС и АСК на болезнетворные бактерии более выражено, чем у диклофенака. Ингибирование болезнетворных бактерий микробиома молекулой ГС способствует снижению воспаления.

пребиотические эффектымикробиом человекаплощадь под кривой ростахемоинформатикаанализа ≪больших данных≫глюкозамина сульфатСустагард Артроprebiotic effectshuman microbiomearea under the growth curvechemoinformaticsbig data analysisglucosamine sulfateSustagard ArthroРабота выполнена при поддержке гранта РФФИ 18-07-00929.The study was supported by the grant provided by the Russian Foundation for Basic Research 18-07-00929.ReferencesLiu J., Lahousse L., Nivard M.G., Bot M., Chen L., van Klinken J.B., Thesing C.S., Beekman M., van den Akker E.B., Slieker R.C., Waterham E., van der Kallen C.J.H., de Boer I., Li-Gao R., Vojinovic D., Amin N., Radjabzadeh D., Kraaij R., Alferink L.J.M., Murad S.D., Uitterlinden A.G., Willemsen G., Pool R., Milaneschi Y., van Heemst D., Suchiman H.E.D., Rutters F., Elders P.J.M., Beulens J.W.J., van der Heijden A.A.W.A., van Greevenbroek M.M.J., Arts I.C.W., Onderwater G.L.J., van den Maagdenberg A.M.J.M., Mook-Kanamori D.O., Hankemeier T., Terwindt G.M., Stehouwer C.D.A., Geleijnse J.M., 't Hart L.M., Slagboom P.E., van Dijk K.W., Zhernakova A., Fu J., Penninx B.W.J.H., Boomsma D.I., Demirkan A., Stricker B.H.C., van Duijn C.M. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. Nat Med. 2020 Jan; 26 (1): 110–117. https://doi.org/10.1038/s41591-019-0722-x. Epub 2020 Jan 13. PubMed PMID: 31932804.Liu J., Lahousse L., Nivard M.G., Bot M., Chen L., van Klinken J.B., Thesing C.S., Beekman M., van den Akker E.B., Slieker R.C., Waterham E., van der Kallen C.J.H., de Boer I., Li-Gao R., Vojinovic D., Amin N., Radjabzadeh D., Kraaij R., Alferink L.J.M., Murad S.D., Uitterlinden A.G., Willemsen G., Pool R., Milaneschi Y., van Heemst D., Suchiman H.E.D., Rutters F., Elders P.J.M., Beulens J.W.J., van der Heijden A.A.W.A., van Greevenbroek M.M.J., Arts I.C.W., Onderwater G.L.J., van den Maagdenberg A.M.J.M., Mook-Kanamori D.O., Hankemeier T., Terwindt G.M., Stehouwer C.D.A., Geleijnse J.M., 't Hart L.M., Slagboom P.E., van Dijk K.W., Zhernakova A., Fu J., Penninx B.W.J.H., Boomsma D.I., Demirkan A., Stricker B.H.C., van Duijn C.M. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. Nat Med. 2020 Jan; 26 (1): 110–117. https://doi.org/10.1038/s41591-019-0722-x. Epub 2020 Jan 13. PubMed PMID: 31932804.Dworsky-Fried Z., Kerr B.J., Taylor A.M.W. Microbes, microglia, and pain. Neurobiol Pain. 2020; 7: 100045. Published 2020 Jan 29. https://doi.org/10.1016/j.ynpai.2020.100045.Dworsky-Fried Z., Kerr B.J., Taylor A.M.W. Microbes, microglia, and pain. Neurobiol Pain. 2020; 7: 100045. Published 2020 Jan 29. https://doi.org/10.1016/j.ynpai.2020.100045.Hernandez C.J. The Microbiome and Bone and Joint Disease. Curr Rheumatol Rep. 2017; 19 (12): 77. Published 2017 Nov 4. https://doi.org/10.1007/s11926-017-0705-1.Hernandez C.J. The Microbiome and Bone and Joint Disease. Curr Rheumatol Rep. 2017; 19 (12): 77. Published 2017 Nov 4. https://doi.org/10.1007/s11926-017-0705-1.Громова О.А., Торшин И.Ю., Гарасько Е.А. Молекулярные механизмы разрушения бактериальных пленок при топическом применении аскорбиновой кислоты. Гинекология. 2010; 12 (6): 12–17.Gromova O.A., Torshin I.Yu., Garasko E.A. Molecular mechanisms of destruction of bacterial films with topical application of ascorbic acid. Ginekologia. 2010; 12 (6): 12-17. (In Russ) ID:15596416Dubreuil M., Louie-Gao Q., Peloquin C.E., Choi H.K., Zhang Y., Neogi T. Risk of myocardial infarction with use of selected nonsteroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis. 2018;77(8):1137-1142. https://ard.bmj.com/content/77/8/1137Dubreuil M., Louie-Gao Q., Peloquin C.E., Choi H.K., Zhang Y., Neogi T. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis. 2018;77(8):1137-1142. https://ard.bmj.com/content/77/8/1137Horvath A., Leber B., Feldbacher N., Steinwender M., Komarova I., Rainer F., Blesl A., Stadlbauer V. The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. Sci Rep. 2020 Feb 17; 10 (1): 2723. http://dx.doi.org/10.1136/annrheumdis-2018-213089.Horvath A., Leber B., Feldbacher N., Steinwender M., Komarova I., Rainer F., Blesl A., Stadlbauer V. The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. Sci Rep. 2020 Feb 17; 10 (1): 2723. http://dx.doi.org/10.1136/annrheumdis-2018-213089.Szychlinska M.A., Di Rosa M., Castorina A., Mobasheri A., Musumeci G. A correlation between intestinal microbiota dysbiosis and osteoarthritis. Heliyon. 2019 Jan 12; 5 (1): e01134. https://doi.org/10.1016/j.heliyon.2019.e01134.Szychlinska M.A., Di Rosa M., Castorina A., Mobasheri A., Musumeci G. A correlation between intestinal microbiota dysbiosis and osteoarthritis. Heliyon. 2019 Jan 12; 5 (1): e01134. https://doi.org/10.1016/j.heliyon.2019.e01134.Simoni G., Maccauro G., Fenga D., De Santis V., Orani R.A., Centofanti F., Rosa M.A. Arthrodesis of the ankle joint in septic osteoarthritis: six years long term outcomes in authors' personal experience. Eur Rev Med Pharmacol Sci. 2019 Apr; 23 (2 Suppl): 139–144. https://doi.org/10.26355/eurrev_201904_17483.Simoni G., Maccauro G., Fenga D., De Santis V., Orani R.A., Centofanti F., Rosa M.A. Arthrodesis of the ankle joint in septic osteoarthritis: six years long term outcomes in authors' personal experience. Eur Rev Med Pharmacol Sci. 2019 Apr; 23 (2 Suppl): 139–144. https://doi.org/10.26355/eurrev_201904_17483.Hu S., Wang J., Xu Y., et al. Anti-inflammation effects of fucosylated chondroitin sulphate from Acaudina molpadioides by altering gut microbiota in obese mice. Food Funct. 2019; 10 (3): 1736–1746. https://doi.org/10.1039/c8fo02364f.Hu S., Wang J., Xu Y., et al. Anti-inflammation effects of fucosylated chondroitin sulphate from Acaudina molpadioides by altering gut microbiota in obese mice. Food Funct. 2019; 10 (3): 1736–1746. https://doi.org/10.1039/c8fo02364f.Maier L., Pruteanu M., Kuhn M., Zeller G., Telzerow A., Anderson E.E., Brochado A.R., Fernandez K.C., Dose H., Mori H., Patil K.R., Bork P., Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29; 555 (7698): 623–628. https://doi.org/10.1038/nature25979.Maier L., Pruteanu M., Kuhn M., Zeller G., Telzerow A., Anderson E.E., Brochado A.R., Fernandez K.C., Dose H., Mori H., Patil K.R., Bork P., Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29; 555 (7698): 623–628. https://doi.org/10.1038/nature25979.Торшин И. Ю., Громова О. А., Захарова И. Н., Максимов В. А. Хемомикробиомный анализ Лактитола. Экспериментальная и клиническая гастроэнтерология. 2019; 164 (4): 111–121. https://doi.org/10.31146/1682-8658-ecg-164-4-111-121Torshin I. Yu., Gromova O. A., Zakcharova I. N., Maximov V. A. Hemomikrobiomny lactitol analysis. Experimental and Clinical Gastroenterology. 2019; 164 (4): 111–121. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-164-4-111-121.Torshin I.Yu., Rudakov K.V. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognition and Image Analysis. 2015; 25 (4): 577–587.Torshin I.Yu., Rudakov K.V. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognition and Image Analysis. 2015; 25 (4): 577–587.Torshin I.Y., Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2017; 27 (1): 16–28.Torshin I.Y., Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2017; 27 (1): 16–28.Torshin I.Yu, Rudakov K.V. On metric spaces arising during formalization of problems of recognition and classification. Part 2: Density properties. Pattern Recognit. Image Anal. 2016; 26 (3): 483–496.Torshin I.Yu, Rudakov K.V. On metric spaces arising during formalization of problems of recognition and classification. Part 2: Density properties. Pattern Recognit. Image Anal. 2016; 26 (3): 483–496.Torshin I.Y. The study of the solvability of the genome annotation problem on sets of elementary motifs. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2011; 21 (4): 652–662.Torshin I.Y. The study of the solvability of the genome annotation problem on sets of elementary motifs. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2011; 21 (4): 652–662.Torshin I.Yu, Rudakov K.V. On the procedures of generation of numerical features over the splits of a set of objects and the problem of prediction of numeric target variables. Pattern Recognition and Image Analysis. 2019; 29 (2): 65–75.Torshin I.Yu, Rudakov K.V. On the procedures of generation of numerical features over the splits of a set of objects and the problem of prediction of numeric target variables. Pattern Recognition and Image Analysis. 2019; 29 (2): 65–75.Kim S., Chen J., Cheng T., Gindulyte A., He J., He S., Li Q., Shoemaker B.A., Thiessen P.A., Yu B., Zaslavsky L., Zhang J., Bolton E.E. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019 Jan 8; 47 (D1): D1102–D1109. https://doi.org/10.1093/nar/gky1033Kim S., Chen J., Cheng T., Gindulyte A., He J., He S., Li Q., Shoemaker B.A., Thiessen P.A., Yu B., Zaslavsky L., Zhang J., Bolton E.E. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019 Jan 8; 47 (D1): D1102–D1109. https://doi.org/10.1093/nar/gky1033.A framework for human microbiome research. Nature. 2012 Jun 13; 486 (7402): 215–21. https://doi.org/10.1038/nature11209.A framework for human microbiome research. Nature. 2012 Jun 13; 486 (7402): 215–21. https://doi.org/10.1038/nature11209.The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe. 2014 Sep 10; 16 (3): 276–89. https://doi.org/10.1016/j.chom.2014.08.014.The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe. 2014 Sep 10; 16 (3): 276–89. https://doi.org/10.1016/j.chom.2014.08.014.Otani K., Tanigawa T., Watanabe T., Shimada S., Nadatani Y., Nagami Y., Tanaka F., Kamata N., Yamagami H., Shiba M., Tominaga K., Fujiwara Y., Arakawa T. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017; 95 (1): 22–28. https://doi.org/10.1159/000452356.Otani K., Tanigawa T., Watanabe T., Shimada S., Nadatani Y., Nagami Y., Tanaka F., Kamata N., Yamagami H., Shiba M., Tominaga K., Fujiwara Y., Arakawa T. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017; 95 (1): 22–28. https://doi.org/10.1159/000452356.Reuter B.K., Davies N.M., Wallace J.L. Nonsteroidal antiinflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology. 1997; 112: 109–117.Reuter B.K., Davies N.M., Wallace J.L. Nonsteroidal antiinflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology. 1997; 112: 109–117.Hersoug L.G., Møller P., Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev. 2016 Apr; 17 (4): 297-312. https://doi.org/10.1111/obr.12370.Hersoug L.G., Møller P., Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev. 2016 Apr; 17 (4): 297-312. https://doi.org/10.1111/obr.12370.Zhang D.M., Jiao R.Q., Kong L.D. High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions. Nutrients. 2017 Mar 29; 9 (4). pii: E335. https://doi.org/10.3390/nu9040335.Zhang D.M., Jiao R.Q., Kong L.D. High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions. Nutrients. 2017 Mar 29; 9 (4). pii: E335. https://doi.org/10.3390/nu9040335.Громова О.А., Торшин И.Ю., Лила А.М. и др. Дифференциальный хемореактомный анализ глюкозамина сульфата и нестероидных противовоспалительных препаратов: перспективные синергичные комбинации. Современная ревматология. 2018; 12 (2): 36–43 https://doi.org/10.14412/1996-7012-2018-2-36-43.Gromova O.A., Torshin I.Yu., Lila A.M., et al. Differential chemoreactome analysis of glucosamine sulfate and non-steroidal antiinflammatory drugs: promising synergistic drug combinations. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018; 12 (2): 36–43 (In Russ). https://doi.org/10.14412/1996-7012-2018-2-36-43.Громова О.А., Торшин И.Ю., Лила А.М., Громов А.Н. Молекулярные механизмы глюкозамина сульфата при лечении дегенеративно-дистрофических заболеваний суставов и позвоночника: результаты протеомного анализа. Неврология, нейропсихиатрия, психосоматика. 2018; 10 (2): 38–44. https://doi.org/10.14412/2074-2711-2018-2-38-44.Gromova O.A., Torshin I.Yu., Lila A.M., Gromov A.N. Molecular mechanisms of action of glucosamine sulfate in the treatment of degenerative-dystrophic diseases of the joints and spine: results of proteomic analysis. Neurology, Neuropsychiatry, Psychosomatics. 2018; 10 (2): 38–44. (In Russ.) https://doi.org/10.14412/2074-2711-2018-2-38-44.Bell G.A., Kantor E.D., Lampe J.W., Shen D.D., White E. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012 Aug; 27 (8): 593-603. https://doi.org/10.1007/s10654-012-9714-6.Bell G.A., Kantor E.D., Lampe J.W., Shen D.D., White E. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012 Aug; 27 (8): 593–603. https://doi.org/10.1007/s10654-012-9714-6.Государственная фармакопея Российской Федерации. 14-е изд. Том 1. М. 2018. State Pharmacopoeia of the Russian Federation. 14th ed. Vol. 1. Moscow; 2018. (In Russ).State Pharmacopoeia of the Russian Federation. 14th ed. Vol. 1. Moscow; 2018. (In Russ).Reginster J.L., Bruyere O., Cooper C. Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Ann Rheum Dis. 2018; 77 (7): e39. https://doi.org/10.1136/annrheumdis-2017-212251.Reginster J.L., Bruyere O., Cooper C. Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Ann Rheum Dis. 2018; 77 (7): e39. https://doi.org/10.1136/annrheumdis-2017-212251.Bruyère O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337–350. https://doi.org/10.1016/j.semarthrit.2019.04.008.Bruyère O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337–350. https://doi.org/10.1016/j.semarthrit.2019.04.008.

The authors declare that there are no conflicts of interest present.